1939-16-8

Basic information

• Product Name: 1-bibenzyl-α-yl-pyrrolidine
• CAS NO: 1939-16-8
• Molecular Weight: 251.371
• Mol File: 1939-16-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-bibenzyl-α-yl-pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bibenzyl-α-yl-pyrrolidine(1939-16-8)
• EPA Substance Registry System: 1-bibenzyl-α-yl-pyrrolidine(1939-16-8)

Safety Data

• Hazardous Substances Data: 1939-16-8(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 451-40-1 phenyl benzyl ketone 
• 58268-28-3 (E)-1-(1,2-diphenylvinyl)pyrrolidine 
• 501-65-5 diphenyl acetylene 
• 3389-54-6 n-benzoylpyrrolidine 
• 6921-34-2 benzylmagnesium chloride 

Relevant articles and documents

Tertiary amine synthesis: Via reductive coupling of amides with Grignard reagents

A new iridium catalyzed reductive coupling reaction of Grignard reagents and tertiary amides affording functionalised tertiary amine products via an efficient and technically-simple one-pot, two-stage experimental protocol, is reported. The reaction-which can be carried out on gram-scale using as little as 1 mol% Vaska's complex [IrCl(CO)(PPh3)2] and TMDS as the terminal reductant for the initial reductive activation step-tolerates a broad range of tertiary amides from (hetero)aromatic to aliphatic (branched, unbranched and formyl) and a wide variety of alkyl (linear, branched), vinyl, alkynyl and (hetero)aryl Grignard reagents. The new methodology has been applied directly to bioactive molecule synthesis and the high chemoselectivity of the reductive coupling of amide has been exploited in late stage functionalization of drug molecules. This reductive functionalisation of tertiary amides provides a new and practical solution to tertiary amine synthesis.

1,2-diarylethylamines for treatment of neurotoxic injury

Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of a 1,2-diarylethylamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites. Compounds of interest are those of the formula wherein each of R1 and R2 is a group independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, hydroxyl, alkoxy, halo, cyano, nitro and mercapto, or wherein R1 and R2 may be taken together to form an oxo group or to form a saturated or partially unsaturated carbocyclic group having three to eight ring carbons; wherein each of Ar1 and Ar2 is a group independently selected from aryl and heteroaryl having one or two heteroatoms selected from N, O and S; and wherein any of the foregoing Ar1 and Ar2 groups having a substitutable position msy be substituted with one or more radicals selected from hydrido, alkyl, cycloalkyl, halo, haloalkyl, alkenyl, alkynyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl, amino, cyano, nitro and mercapto; wherein X is selected from CH, CH2, NH, O and S, to form a ring having five to eight members provided that such ring is saturated or contains one double bond or is benzo-fused; and wherein Y is one or more a groups selected from hydrido, alkyl, cycloalkyl, halo, haloalkyl, alkenyl, alkynyl, hydroxyl, hydroxy-alkyl, alkoxy, alkoxyalkyl, amino, cyano, nitro and mercapto; or a pharmaceutically acceptable salt thereof.